1. Home
  2. IMXI vs DMAC Comparison

IMXI vs DMAC Comparison

Compare IMXI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.50

Market Cap

460.6M

Sector

Technology

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.62

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
DMAC
Founded
1994
2000
Country
US
US
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.6M
428.6M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
IMXI
DMAC
Price
$15.50
$8.62
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$16.67
$15.50
AVG Volume (30 Days)
192.9K
184.3K
Earning Date
01-01-0001
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
9.82
N/A
EPS
0.79
N/A
Revenue
$319,601,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.95
N/A
P/E Ratio
$19.63
N/A
Revenue Growth
16.68
N/A
52 Week Low
$8.58
$3.22
52 Week High
$18.48
$10.42

Technical Indicators

Market Signals
Indicator
IMXI
DMAC
Relative Strength Index (RSI) 50.88 53.95
Support Level $15.52 $8.00
Resistance Level $15.63 $9.04
Average True Range (ATR) 0.05 0.55
MACD -0.01 0.05
Stochastic Oscillator 30.56 69.11

Price Performance

Historical Comparison
IMXI
DMAC

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: